Finance

Lists
Why is 600812 up 10.04%?
Dive Deeper
600812:SHA
North China Pharmaceutical Co Ltd
CN¥6.03
+10.04%
(+0.55) 1D
Oct 9, 2:25:10 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 600812...
Open
CN¥5.60
High
CN¥6.03
Low
CN¥5.58
Avg. vol.
38.76M
Volume
114.85M
Dividend
0.58%
Quarterly dividend
CN¥0.01
Ex-dividend date
Jun 11, 2026
P/E ratio
84.05
52-wk high
CN¥6.29
52-wk low
CN¥4.11
EPS
CN¥0.07
Shares outstanding
1.63B
No. of employees
10K
Open
CN¥5.60
High
CN¥6.03
Low
CN¥5.58
Avg. vol.
38.76M
Volume
114.85M
Dividend
0.58%
Quarterly dividend
CN¥0.01
Ex-dividend date
Jun 11, 2026
P/E ratio
84.05
52-wk high
CN¥6.29
52-wk low
CN¥4.11
EPS
CN¥0.07
Shares outstanding
1.63B
No. of employees
10K
News stories
From web sources and news partners
Profile
North China Pharmaceutical Group Corp., is a pharmaceutical manufacturer in China. NCPC was one of the key construction projects during China's First Five-Year Plan. After five years of construction since the foundation date in June 1953, the first successful pharmaceutical production, started in June 1958. Being one of the antibiotic producers both in technology and production scale at that time, NCPC created a history of commercial production of antibiotics in China. It has 45 years of development experience. NCPC has been taking the lead in the Chinese pharmaceutical industry in key economic indexes, ranked as one of the Top500 Enterprises and the best profit-makers in China. By the end of 2002, the total assets of the company were valued at US$2 billion, with 18,500 employees. In 2002, NCPC claimed a domestic sales revenue of US$700 million and export sales of US$100 million. Wikipedia
About North China Pharmaceutical Co Ltd
CEO-
Employees9.97K
FoundedDec 20, 1992
Headquarters-
SectorPharmaceutical industry
Website-
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
2.21B
1.76B
2.15B
2.07B
Cost of goods sold
1.59B
1.07B
1.53B
1.54B
Cost of revenue
1.59B
1.07B
1.53B
1.54B
Research and development expenses
85.19M
85.95M
95.62M
84.71M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
419.54M
414.91M
354.22M
304.68M
Operating expense
504.74M
539.54M
495.25M
396.76M
Total operating expenses
2.09B
1.61B
2.03B
1.94B
Operating income
116.01M
149.57M
128.11M
125.58M
Other non operating income
-299.86K
-2.96M
-10.58M
6.02M
EBT including unusual items
73.18M
70.19M
66.28M
57.65M
EBT excluding unusual items
45.54M
84.31M
61.80M
58.08M
Income tax expense
23.93M
24.28M
16.90M
16.15M
Effective tax rate
32.70%
34.59%
25.50%
28.02%
Other operating expenses
4.82M
29.30M
27.82M
15.57M
Net income
35.01M
24.55M
35.47M
28.37M
Net profit margin
1.58%
1.40%
1.65%
1.37%
Earnings per share
-
-
-
-
Interest and investment income
19.41M
27.71M
19.26M
22.40M
Interest expense
-85.85M
-85.06M
-74.99M
-76.52M
Net interest expenses
-66.43M
-57.35M
-55.73M
-54.13M
Depreciation and amortization charges
-
-
-
-
EBITDA
313.14M
371.92M
350.45M
367.38M
Gain or loss from assets sale
-9.85K
-827.34K
-
-217.80K
AI content may include mistakes. Learn more
Google apps